CTOR

Citius Oncology (CTOR)

About Citius Oncology (CTOR)

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Details

Daily high

$1.12

Daily low

$1.00

Price at open

$1.11

52 Week High

$6.19

52 Week Low

$0.55

Market cap

89.0M

Dividend yield

0.00%

Volume

350,582

Avg. volume

712,643

P/E ratio

-5.51

Citius Oncology News